Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OptimizeRx Corp Director's Dealing 2024

Feb 14, 2024

33090_dirs_2024-02-13_c5e6ae41-ff1b-488a-9d4a-64c2fbcbd53d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2024-02-11

Reporting Person: Odence-Ford Marion (General Counsel and CCO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-11 Common Stock M 4000 Acquired 15114 Direct
2024-02-11 Common Stock F 1386 $15.39 Disposed 13728 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-11 Restricted Stock Units $ M 4000 Disposed Common Stock (4000) Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended.

F3: On February 11, 2021, the reporting person was granted 20,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.